Biomarkers and immunopathology of tolerance.
Biomarkers and immunopathology of tolerance.
复制标题
耐受性的生物标志物和免疫病理学。
DOI：
10.1097/mot.0000000000000269
复制
发表时间：
2016
影响因子：
2.2
通讯作者：
Mastoridis S
中科院分区：
文献类型：
--
作者：
Mastoridis S
最近在鉴定稳健的耐受性生物标志物方面取得了重大进展。认识到需要对这些进行严格验证，第一个生物标志物主导的前瞻性免疫抑制戒断试验正在进行中。这些项目有望在耐受性生物标志物发现方面取得进一步进展和完善，并为改善与免疫抑制治疗相关的负担提供希望。
Significant recent progress in identifying robust tolerance biomarkers has been made. In recognition of the need for rigorous validation of these, the first biomarker-led prospective immunosuppression withdrawal trials are underway. Such projects promise further progress and refinement in tolerance biomarker discovery, and offer hope for the amelioration of the burden associated with immunosuppressive therapies.